secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001104659-22-056484
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports Q1 2022 net loss of $20.6M; cash at $201.3M, runway into Q1 2024
--------------------------------------------------------------------------------

- Net loss of $20.6M vs $16.5M in Q1 2021, driven by higher R&D expenses.
- Cash, cash equivalents and securities of $201.3M, down $18.3M from Dec 2021.
- On track for H2 2022 milestones: NC318 Phase 2 update, NC410 Phase 1 update, NC762 initial data, NC525 IND filing.
- Cash expected to fund operations into Q1 2024.
- R&D expenses $15.0M (Q1 2022) vs $12.4M (Q1 2021); G&A $5.8M vs $4.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465922056484/0001104659-22-056484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465922056484/tm2214609d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-056484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer